All In Biotech

Drug Trial Radar · NCT06732154

A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects

A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Dec 2, 2024

Primary completion

Mar 2, 2026

Study completion Mar 2, 2026

Sponsor

Sponsor type
Industry
First posted
Dec 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of HRS-5632 Following a Single Subcutaneous Injection in Healthy Subjects

Conditions

  • Dyslipidemia

Interventions

  • HRS-5632Drug

    HRS-5632 Injection

  • PlaceboDrug

    Sodium chloride injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage of all reported adverse events, serious adverse events and treatment-related adverse events, serious adverse events.Time frame: from the single dose administration (Day 1) to Day 337

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.